Lung Cancer Clinical Trial
Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites
Summary
Evaluate a multi-faceted training program to improve short-term smoking cessation rates (<14 days post-visit) and short (3 months) and sustained abstinence (6 months) among 1,114 enrolled smokers who present for low-dose computed tomography (LDCT) lung cancer screening in 26 community-based practices.
Full Description
We utilize an effectiveness-implementation hybrid design, employing a cluster, randomized control trial of community-based NCORP sites to study the effectiveness of a multi-faceted intervention to improve smoking cessation among lung cancer screening patients, as well as dissemination and implementation (D&I) science to optimize and accelerate translation of findings into clinical practice. We will: (1) Evaluate a multi-faceted training program to improve short-term smoking cessation rates (1-week post-visit) and sustained abstinence (6 months) among 1,114 enrolled smokers (557 in each trial arm) who present for LDCT lung cancer screening in community-based lung cancer screening practices; (2) Characterize the adoption and adaptation of the evidence-based tobacco cessation strategies in 26 community-based LDCT lung cancer screening programs; and (3) Develop and evaluate an implementation toolkit for integrating evidence-based tobacco cessation strategies in community-based LDCT lung cancer screening programs. Qualitative data will be collected from key informants at participating screening programs during and after intervention implementation. Quantitative survey data (baseline, <14 days, 3 months, and 6 months) and saliva specimens (6 months only) will be collected from smoking patients receiving screening within these programs.
Eligibility Criteria
Inclusion Criteria:
Agrees to have NCORP research personnel serve as the study liaison and another person to serve as the cessation program champion.
Agrees to participate in all aspects of the intervention, randomization, and evaluation.
Agrees to participate in a confidential 1-on-1 semi-structured interview with the research team.
Agrees to have the interview taped, transcribed and qualitatively analyzed.
Age ≥18 years
Potential participants will be screened using the following question: "Do you smoke cigarettes every day, some days, or not at all?" (BRFSS). A current smoker is anyone responds "every day" or "some days".
Exclusion Criteria:
Current use (previous 30 days) of a tobacco dependence treatment including bupropion, varenicline, and nicotine replacement
Individuals who use e-cigarettes and who are not smoking cigarettes. Dual users (those who use both e-cigarettes and cigarettes) will still be included in the trial.
The presence of a physical or cognitive impairment that would prevent a person from engaging in survey research (such as blindness, deafness, or dementia).
Individual has already completed the intended LDCT lung cancer screening for this study.
Non-English speaking participants.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 45 Locations for this study
Newark Delaware, 19713, United States
Augusta Georgia, 30912, United States
Savannah Georgia, 31405, United States
Honolulu Hawaii, 96859, United States
Mount Vernon Illinois, 62864, United States
Urbana Illinois, 61801, United States
Ames Iowa, 50010, United States
Des Moines Iowa, 50314, United States
Shreveport Louisiana, 71103, United States
Ann Arbor Michigan, 48106, United States
Grand Rapids Michigan, 49503, United States
Royal Oak Michigan, 48073, United States
Waconia Minnesota, 55387, United States
Ballwin Missouri, 63011, United States
Bolivar Missouri, 65613, United States
Branson Missouri, 65616, United States
Joplin Missouri, 64804, United States
Joplin Missouri, 64804, United States
Rolla Missouri, 65401, United States
Rolla Missouri, 65401, United States
Saint Louis Missouri, 63109, United States
Saint Louis Missouri, 63131, United States
Saint Louis Missouri, 63141, United States
Springfield Missouri, 65804, United States
Springfield Missouri, 65807, United States
Washington Missouri, 63090, United States
Las Vegas Nevada, 89102, United States
Reno Nevada, 89503, United States
Bronx New York, 10467, United States
Winston-Salem North Carolina, 27103, United States
Fargo North Dakota, 58103, United States
Fargo North Dakota, 58122, United States
Chillicothe Ohio, 45601, United States
Oklahoma City Oklahoma, 73120, United States
Danville Pennsylvania, 17822, United States
Boiling Springs South Carolina, 29316, United States
Clinton South Carolina, 29325, United States
Easley South Carolina, 29640, United States
Greenville South Carolina, 29605, United States
Greenville South Carolina, 29605, United States
Greenville South Carolina, 29605, United States
Greenville South Carolina, 29615, United States
Greer South Carolina, 29650, United States
Seneca South Carolina, 29672, United States
Memphis Tennessee, 38120, United States
Richmond Virginia, 23235, United States
Richmond Virginia, 23298, United States
La Crosse Wisconsin, 54601, United States
Milwaukee Wisconsin, 53215, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.